Kyverna Therapeutics Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Kyverna Therapeutics Inc. | KYTX - NASDAQ |
$20.00-$21.00 | $22.00 | $34.25 | 14.5 million | 2/8/2024 |
| JP Morgan, Morgan Stanley, Leerink Partners, Wells Fargo | ||||||
Co-Manager(s): | ||||||
| Health Care | ||||||
Filing(s): Filed 2024-01-16 Terms Added 2024-02-01 Amended Prospectus 2024-02-06 | ||||||
Kyverna Therapeutics Inc. Quote & Chart - Click for current quote - KYTX
IPO Boutique aggregates information on public companies and private companies, such as "KYTX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Kyverna Therapeutics Inc. (adapted from Kyverna Therapeutics Inc. prospectus):
They are a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "KYTX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.